drugset / Trial / NCT06726148
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Timeline
- Start
- 2025-04-03
- Primary completion
- 2028-09-25
- Completion
- 2028-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ECI830 | Unknown | — | — |
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | Ribociclib | Small molecule | — | — |